<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006157</url>
  </required_header>
  <id_info>
    <org_study_id>CAV-CL-011</org_study_id>
    <nct_id>NCT05006157</nct_id>
  </id_info>
  <brief_title>Pericardial Access With ViaOne Device</brief_title>
  <official_title>Safety and Efficacy of the ViaOne Device for Pericardial Access - a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioVia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioVia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ViaOne device is a tool designed to allow percutaneous subxiphoid pericardial access&#xD;
      utilizing a proprietary mechanism of entry into the pericardial sac. In this study ViaOne&#xD;
      will be used to obtain pericardial access in patients in whom electrophysiological diagnostic&#xD;
      (mapping) and/or therapeutic (ablation) of epicardial sites via percutaneous subxiphoid&#xD;
      approach to the to the normal, non-distended pericardial space is indicated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to provide evidence of safety of ViaOne in obtaining&#xD;
      percutaneous subxiphoid approach to the pericardial space. The secondary objective is to&#xD;
      provide initial estimate of efficacy of ViaOne in obtaining percutaneous subxiphoid approach&#xD;
      to the pericardial space.&#xD;
&#xD;
      Screening procedures will include laboratory analyses of the complete blood count, serum&#xD;
      chemistry, coagulation parameters, and urine or serum ß-HCG test.A physical examination and&#xD;
      collection of vital signs will be conducted. Medical history data and information on&#xD;
      concomitant medications will be collected.&#xD;
&#xD;
      Once eligibility is verified, subjects will be scheduled for a procedure during which&#xD;
      percutaneous subxiphoid pericardial access will be obtained using the ViaOne and its&#xD;
      associated procedure. Time period between the study device insertion through the subxiphoid&#xD;
      incision and guidewire insertion into the pericardial sac, overall time in procedure, and any&#xD;
      procedural complications and device deficiencies will be recorded.&#xD;
&#xD;
      Follow-up visit will be conducted as part of the planned protocol procedures at up 5 ± 1 days&#xD;
      after the procedure or at the time of discharge, whichever comes first. The visit will&#xD;
      include evaluation of any adverse events and complications. Length of hospital stay will be&#xD;
      recorded, where the discharge precedes or coincides with the final follow-up visit of the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2021</start_date>
  <completion_date type="Anticipated">February 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of ViaOne device</measure>
    <time_frame>through study completion, an average of 5 days</time_frame>
    <description>Incidence of device-related adverse events through study completion, an average of 5 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial Efficacy of ViaOne device</measure>
    <time_frame>through study completion, an average of 5 days</time_frame>
    <description>Rate of success of pericardial space access, defined as guidewire insertion into the pericardial space.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pericardial Access</condition>
  <arm_group>
    <arm_group_label>ViaOne device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ViaOne device will be used for percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ViaOne device</intervention_name>
    <description>ViaOne device is designed to allow percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac.</description>
    <arm_group_label>ViaOne device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 21&#xD;
&#xD;
          2. Electrophysiological diagnostic (mapping) and/or therapeutic (ablation) of epicardial&#xD;
             sites via percutaneous subxiphoid approach to the to the normal, non-distended&#xD;
             ericardial space is indicated.&#xD;
&#xD;
          3. Pre-treatment coagulation values within the following limits:&#xD;
&#xD;
               -  international normalized ratio 0.8 - 1.2&#xD;
&#xD;
               -  partial thromboplastin time 25 - 35''&#xD;
&#xD;
          4. Pre-treatment hematology and biochemistry values within the following limits:&#xD;
&#xD;
               -  hemoglobin ≥ 10 g/dL (g/100 mL)&#xD;
&#xD;
               -  platelets ≥ 150 x 10^9/L (x 10^3/mm^3)&#xD;
&#xD;
               -  white blood cells ≥ 3.0 x 10^9/L (x 10^3/mm^3)&#xD;
&#xD;
               -  absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1.5 x 10^3/mm^3)&#xD;
&#xD;
               -  serum creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
               -  aspartate aminotransferase &lt; 1.5 x ULN (upper limit of norm)&#xD;
&#xD;
               -  alanine aminotransferase &lt; 1.5 x ULN&#xD;
&#xD;
               -  alkaline phosphatase &lt; 1.5 x ULN&#xD;
&#xD;
          5. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cardiac or pericardial surgery or prior pericardial ablation.&#xD;
&#xD;
          -  History of chronic pericarditis.&#xD;
&#xD;
          -  Known pericardial fibrosis and/or adhesions.&#xD;
&#xD;
          -  Any anomaly in the chest anatomy.&#xD;
&#xD;
          -  Myocardial infarction, past or present.&#xD;
&#xD;
          -  Bleeding disorders.&#xD;
&#xD;
          -  Hepatic enlargement.&#xD;
&#xD;
          -  BMI &gt; 40&#xD;
&#xD;
          -  Participation in another interventional trial.&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Luria</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah MC, Jerusalem, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ziv Menshes</last_name>
    <phone>+(972) 524807162</phone>
    <email>ziv@cardiovia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Or Hazan</last_name>
    <phone>+(972) 548081465</phone>
    <email>or@cardiovia.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah Ein Kerem MC</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galina levin</last_name>
      <email>Lenving@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Ayelet Shauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek MC</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lea Dotan</last_name>
      <email>cardioresearch@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Michael Glikson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 15, 2021</last_update_submitted>
  <last_update_submitted_qc>August 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pericardial space</keyword>
  <keyword>pericardial access</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

